Laboratory Parameters During First Rituximab Infusion
| Parameter . | Normal Range . | Group A . | Group B . | 2-Tailed P Value A v B3-150 . | ||||
|---|---|---|---|---|---|---|---|---|
| Median Prior Rituximab . | Median Postrituximab . | Change . | Median Prior Rituximab . | Median Postrituximab . | Change . | |||
| LDH | (120-240 U/L) | 283 | 364 | +81 | 318 | 772 | +454 | .213 |
| AST | (<16 U/L) | 12 | 13 | +1 | 10 | 34 | +24 | .137 |
| ALT | (<20 U/L) | 9 | 7 | −2 | 9 | 28 | +19 | .075 |
| γ-GT | (<19 U/L) | 11 | 12 | +1 | 19 | 48 | +29 | .094 |
| D-dimers | (<0.6 mg/L) | 1.9 | 2.1 | +0.2 | 1.2 | 9.4 | +8.2 | .234 |
| Calcium | (2.2-2.6 mmol/L) | 2.48 | 2.20 | −0.28 | 2.35 | 1.93 | −0.42 | .233 |
| Protein | (66-83 g/L) | 62 | 57 | +5 | 69 | 55 | −14 | .049 |
| CRP | (<8 mg/L) | 13 | 30 | +17 | 8 | 38 | +30 | .474 |
| Uric acid | (<6.1 mg/dL) | 6.4 | 5.7 | −0.7 | 6.1 | 7.4 | +1.3 | .052 |
| Hemoglobin | (12-16 g/dL) | 9.9 | 9.8 | −0.1 | 10.3 | 9.0 | −1.3 | .140 |
| Prothrom time | (70-120%) | 95 | 90 | −5 | 90 | 71 | −19 | .126 |
| Potassium | (3.6-4.8 mmol/L) | 4.0 | 4.3 | +0.3 | 4.0 | 3.8 | −0.2 | .076 |
| C3 complement | (0.75-1.40 g/L) | 0.862 | 0.674 | −0.19 | 0.803 | 0.582 | −0.22 | .249 |
| C4 complement | (0.10-0.34 g/L) | 0.566 | 0.263 | −0.30 | 0.714 | 0.252 | −0.46 | .272 |
| Parameter . | Normal Range . | Group A . | Group B . | 2-Tailed P Value A v B3-150 . | ||||
|---|---|---|---|---|---|---|---|---|
| Median Prior Rituximab . | Median Postrituximab . | Change . | Median Prior Rituximab . | Median Postrituximab . | Change . | |||
| LDH | (120-240 U/L) | 283 | 364 | +81 | 318 | 772 | +454 | .213 |
| AST | (<16 U/L) | 12 | 13 | +1 | 10 | 34 | +24 | .137 |
| ALT | (<20 U/L) | 9 | 7 | −2 | 9 | 28 | +19 | .075 |
| γ-GT | (<19 U/L) | 11 | 12 | +1 | 19 | 48 | +29 | .094 |
| D-dimers | (<0.6 mg/L) | 1.9 | 2.1 | +0.2 | 1.2 | 9.4 | +8.2 | .234 |
| Calcium | (2.2-2.6 mmol/L) | 2.48 | 2.20 | −0.28 | 2.35 | 1.93 | −0.42 | .233 |
| Protein | (66-83 g/L) | 62 | 57 | +5 | 69 | 55 | −14 | .049 |
| CRP | (<8 mg/L) | 13 | 30 | +17 | 8 | 38 | +30 | .474 |
| Uric acid | (<6.1 mg/dL) | 6.4 | 5.7 | −0.7 | 6.1 | 7.4 | +1.3 | .052 |
| Hemoglobin | (12-16 g/dL) | 9.9 | 9.8 | −0.1 | 10.3 | 9.0 | −1.3 | .140 |
| Prothrom time | (70-120%) | 95 | 90 | −5 | 90 | 71 | −19 | .126 |
| Potassium | (3.6-4.8 mmol/L) | 4.0 | 4.3 | +0.3 | 4.0 | 3.8 | −0.2 | .076 |
| C3 complement | (0.75-1.40 g/L) | 0.862 | 0.674 | −0.19 | 0.803 | 0.582 | −0.22 | .249 |
| C4 complement | (0.10-0.34 g/L) | 0.566 | 0.263 | −0.30 | 0.714 | 0.252 | −0.46 | .272 |
Abbreviations: LDH, lactate dehydrogenase; AST, aspartate transaminase; ALT, alanine transaminase; γ-GT, γ-glutamyltranspeptidase; CRP, C-reactive protein.
P values compare the changes of the laboratory parameters during rituximab treatment in group A v group B patients.